ZyVersa Therapeutics(ZVSA.US)

Company Encyclopedia
View More
name
ZyVersa Therapeutics
ZVSA.US
ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company that develops and commercializes products for the treatment of renal and inflammatory diseases. The company develops drug development platforms, including Cholesterol Efflux Mediator VAR 200, an injectable drug, which is in Phase 2a clinical trial for the treatment of renal indications, such as focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney diseases; and Inflammasome ASC Inhibitor IC 100, a humanized monoclonal antibody that is in preclinical stage for treatment of inflammatory diseases comprising acute respiratory syndrome, multiple sclerosis, pancreatic cancer, Parkinson’s and Huntington’s disease, atherosclerosis, Alzheimer’s disease, and obesity. The company has a license agreement with L&F Research LLC, and InflamaCORE, LLC.
1.896 T
ZVSA.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ZyVersa Therapeutics Director Robert Finizio Resigns

    ZyVersa Therapeutics Inc. announced the resignation of Robert G. Finizio from his roles as independent director, Chairman of the Compensation Committee, and member of the Audit Committee, effective immediately. His departure is due to personal reasons and not related to any disagreements with the company.

    Reuters·
    US
    ZVSA
    +0.23%
    Reuters·
    US
    ZVSA
    +0.23%

    ZyVersa Therapeutics Reports Third Quarter 2025 Financial Results

    WESTON, Fla., Nov. 19, 2025 ( GLOBE NEWSWIRE ) -- ZyVersa Therapeutics, Inc. ( OTCQB: ZVSA, or "ZyVersa" ) , a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, reports ...

    GlobeNewswire·
    US
    ZVSA
    +0.23%
    GlobeNewswire·
    US
    ZVSA
    +0.23%

    ZyVersa Therapeutics | 8-K: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ZVSA
    +0.23%
    LB filings·
    US
    ZVSA
    +0.23%

    ZyVersa Therapeutics | 10-Q: FY2025 Q3 Revenue: USD 0

    LB filings·
    US
    ZVSA
    +0.23%
    LB filings·
    US
    ZVSA
    +0.23%

    ZyVersa Therapeutics posts $20.7 million pre-tax loss for Q3 2025

    ZyVersa Therapeutics reported a pre-tax loss of $20.7 million for Q3 2025, up from $2.4 million in Q3 2024, mainly due to an $18.6 million impairment in R&D. Cash on hand was $0.5 million. The company raised $2.1 million in Q3 and $4.1 million YTD. ZyVersa is advancing its pipeline and seeking additional financing.

    Reuters·
    US
    ZVSA
    +0.23%
    Reuters·
    US
    ZVSA
    +0.23%
    © 2026 Longbridge｜Disclaimer